red headed step child here, uninvited guest on the Adxs board.....one last thing .......
if Adxs is trading at $10 , announcement of FDA green light....$14-$15 is realistic close. Done.
The patient death is NOT why the trial is on hold. Chinaman posted why and he is 100% correct.
" . . . . a surprise to everyone that the adxs listeria survived in that patient for 3 yrs, there has to be some resolution on that before we move forward." - , - the (nose under the big tent) weasl.
" hey rbruff .. good to hear from you. Our Trvn is going to be fine. You own* 1k @ $5.85" - 8/10/15
I didn't want to buy on margin [trial results are never absolute] but we definitely missed out on Trvn, a smooth 100% upside after ph II results. 100% within one month, a record I'll never break.
The point ? At first read I was disappointed .......after sleeping on it, it's 'ok'. Full of words like 'can', 'potential' [possibility], 'hypothesis' [belief] -
We've got plenty of time to figure this out. Remember, it's what the company doesn't tell you that's as important as reported data. Was there an increase in til's ? .. .. . . . . .
The point ? Definitions for the board to read (PR, SD) ....we also went up against a "highly aggressive" cancer and I have no doubt the patients were nearing the e .. . . . . : (
After reading the MCC abstract/data ..' EP-IL/12 leads to regression of . . .non injected tumors.'... . . Dr. Meininger joining Oncs .,, confirmation of success (?)...possibly...or probably....hmm . .glta.
Trvn, today's close is the 100% upside update. This reminds me of a song by the band Ministry (1989), titled SO WHAT ! They played loud music, stop, scream SO WHAT !! and get back to music. - Oncs #1.
guti - U of South Florida news with/ patent is nice, but....we also have two companies competing (engineering) for a new 'go anywhere device - The competition has increased to three ? Thnks.
Ino was a buy several yrs ago at .50 - their run is over. Punit has plans. EP-IL12 combo approval in about two yrs. Round numbers, Oncs $6 Ino $7 - update June/Asco .
All Oncs trials are open label, which 'should' lessen the price volatility found in double blind trials.
Ttph down 80% , Akba up 70% on after market news/results. Did he say "frequent updates". . . .
"In the case of Merck's drug, the National Institute for Health and Care Excellence (NICE) said in final draft guidance that it should made available for certain patients with advanced melanoma."
In due time . . . . . .Combination of Keytruda/EP-IL-12 .. . . . .WORLDWIDE.
Enjoy your holiday/birthday on Mon. Thanks for the kind words last week, much appreciated. - I like our chances with Oncosec . .. . there is a serious unrealized upside potential here. Long and holding. GL.
Intraday high $10.29 , 70%+
"The science of Trvn, I read up this past weekend. Earlier P values stat sig. Results of their Ph IIb this quarter. This company is undervalued and a stat sig result will change that. Significantly." 8/4
"A line in the sand. Holding. Two possible outcomes, 1) bankrupt 2) own the bank. GL" 8/25 .
The political thread, plenty of good comments .'cept the first one - Lol (c'mon flight, laugh a little : )
rbruf, I looked at my buys and sells going back 5 yrs or so. Time for a new plan. Cldx at $3.95, sold around $6...hit $40 last year(?) Acad 5k #$%$ $2.50,,, hit endpoints, sold at $8..eventually ran to $50 (a cool quarter mill, whoops) there are others. A line in the sand. Holding.
Two possible outcomes, 1) bankrupt 2) own the bank. GL
"We have completed the Phase 2 monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. We will present two poster presentations entitled “Demonstration of systemic antitumor immunity via intratumoral regulated expression of IL-12 in advanced breast cancer and melanoma patients” and “Demonstration of systemic antitumor immunity via intratumoral regulated expression of IL-12 as a gene therapy approach to treatment of cancer” at the upcoming CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, Translating Science into Survival, September 16-19, 2015 in NY, NY."
- IL-12 is the name of the game, , , , , Pierce and Algazi are on it.
FDA accepts Merck's sBLA for expanded use of Keytruda, PDUFA date December 19
Aug 18 2015, 09:49 ET | About: Merck & Co Inc. (MRK) | By: Douglas W. House, SA News Editor [Contact this editor with comments or a news tip]
The FDA accepts for review the supplemental Biologics License Application (sBLA) from Merck (MRK -0.1%) seeking approval for the use of Keytruda (pembrolizumab) as first-line treatment of unresectable or metastatic melanoma. The PDUFA date is December 19.
In addition, the FDA extended its action date for a separate sBLA seeking approval for the use of Keytruda for the treatment of ipilimumab-refractory advanced melanoma to December 24.
"I appreciate the point you are trying to make daweasl652, but I think it would be only fair to give this company a bit more time. They just uplisted in the past 90 days, and they released more positive news this morning"
earth457 - While I am disappointed in the initial tute numbers, I agree the 3rd Q totals will more accurately reflect the sentiment of Institutional buying. Maybe we will see the 20% I was hoping for. Thanks for pointing out Ridge and Sabby are hedge funds, therefore not included in the nasdaq totals. Gltu
"We're nearing the 3rd week of Aug.,,,,, combo pr tomorrow soon (tues?)" - my perfect record of predictions continues.
copp - nice post !
Riding what you brought up .... Could it be the more serious side effects were only experienced by those with the initial low til count ? The combo will be high til patients ...could this be Oncs watershed moment - Much lower side effects from Keytruda and an increased response rate. Could this be 'our triple digit stock. GL
Now come on, are you having a bad day? You know the combo will be successful, but I admit, the delay is hard to take." 8/17/15
hey rbruff ...good to hear from you. Our Trvn is going to be fine. You own* 1k @ $5.85 - Read the Adxs board yesterday, wow.... the potential of that co. , triple digits ????
We're nearing the 3rd week of Aug.,,,,, combo pr tomorrow soon (tues?) - Dr. Algazi and Dr. Pierce have confidence this combo will work, I believe it will also. Hopefully UCSF has screened (8,10?) patients and the first enrolled will be the start of several treated this month and next.
* theoretical : )